Business Context and Reporting Period
Company: Oramed Pharmaceuticals Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2025
Event: Entry into a Material Definitive Agreement (Rights Agreement) and declaration of a stock dividend.
Key Financial Metrics
This filing is a current report regarding a corporate governance action and does not contain financial performance data. The following metrics are not applicable or disclosed in this document:
- Revenue, Profit, Cash Flow, Margins: Not disclosed.
- Debt and Liquidity: Not disclosed.
- Dividend Details: Declaration of one common stock purchase right ("Right") per outstanding share of common stock.
- Record Date: November 27, 2025.
- Initial Purchase Price: $10.00 per share of Common Stock.
Material Changes
The primary material change is the implementation of a "poison pill" shareholder rights plan:
- Trigger Threshold: An "Acquiring Person" is defined as any person or group acquiring beneficial ownership of 15% or more of the outstanding Common Stock.
- Flip-In Provision: Upon the acquisition of 15% or more, Rights holders (excluding the Acquiring Person) may purchase shares with a market value of two times the exercise price ($20.00 value for a $10.00 cost).
- Flip-Over Provision: If the Company is acquired in a merger or business combination after an Acquiring Person emerges, Rights holders may purchase shares of the acquiring entity with a market value of two times the exercise price.
- Expiration: Rights expire three years after the Rights Agreement date (November 17, 2025) unless earlier redeemed or exchanged.
Guidance, Outlook, and Risks
Management Commentary: The Board of Directors declared the dividend to protect stockholder interests against unsolicited takeover attempts. The Rights are not exercisable until the "Distribution Date," which occurs 10 business days after a public announcement of an Acquiring Person or a tender offer.
Risks and Contingencies:
- Redemption: The Board may redeem the Rights in whole at $0.012 per Right at any time prior to an Acquiring Person emerging.
- Dilution Protection: The Purchase Price and number of shares issuable are subject to adjustment for stock dividends, subdivisions, or other dilutive events.
- Void Rights: Rights beneficially owned by an Acquiring Person become void upon the triggering event.
Investor Verification Checklist
- Verify the current market price of ORMP common stock relative to the $10.00 exercise price to assess the immediate economic impact of the Rights.
- Confirm the exact Record Date (November 27, 2025) to determine eligibility for the Rights dividend.
- Review the full text of the Rights Agreement (Exhibit 4.1) for specific definitions of "Acquiring Person" and derivative ownership calculations.
- Monitor for any press releases indicating a potential tender offer or accumulation of shares by a single entity exceeding the 15% threshold.
- Check subsequent filings for any Board action to redeem the Rights at the $0.012 price.